Participant Portal Sample Clauses

Participant Portal. What is my role on the Portal ?
Sample 1Sample 2
AutoNDA by SimpleDocs
Participant Portal. Online solution that connects participants to the HCV Program with secure access 24/7, providing the ability to request interims, to view their status on the program and receive HCV Program updates. (HCV Communications)
Sample 1Sample 2
Participant Portal. The Participant Portal is the single-entry point for interactions with the research and innovation programmes of the European Commission. It offers you the possibility to use a great variety of services and tools that facilitate the monitoring and the management of proposals and projects throughout their lifecycle. Depending on the role in projects and organisation, you can view information on projects, negotiate your grant agreement, manage amendments, submit financial and scientific reports or review projects. Access to the portal is based on an ECAS account. ECAS stands for the European Commission's Authentication Service. It provides single sign-on across a large number of Commission information systems: Each user needs to use only one username and password to access different IT systems and once the user has authenticated himself to ECAS, he does not have to re-enter username and password within the same browser session. More information can be found in the ECAS FAQ page.
Sample 1Sample 2
Participant Portal. The Contractor shall be responsible for: a. Configuring and maintaining Participant portal. b. Ensuring an intuitive navigation. c. Providing appropriate security access to Users based on their security role access level and organization assignment(s). d. Providing access to all claims filed by the Participant in the Participant portal, at a minimum, for the previous two plan years and the current plan year. e. Maintaining all claims documentation in accordance with Federal and State retention schedules. f. Providing a home page that includes, at a minimum, a dashboard, account summary, alerts and quick links. g. Supporting State of Florida branding. h. Providing Participant online access to current eligible expenses list. i. Coordinating any ongoing system maintenance and scheduled system downtime with the Department’s already established downtime windows to minimize the impact of providing services.
Sample 1
Participant Portal. At: xxxx://xx.xxxxxx.xx/research/participants/portal/desktop/en/home.html
Sample 1
Participant Portal. SALUSION will provide participants with access to SALUSION’s portal system. This system will allow online claim filing. The participant will also have online access to the following: 1. Real-time history of claim submission and payment process; 2. Account management with transaction history and account balance; 3. Contribution data; and
Sample 1
Participant Portal. For the calls which XxXX has agreed to co-fund, clickable links to the call text are included (see Section III).The call text is also published on the Website of the XxXX. The call text is the same for the EU and Indian applicants. In order to get a grant from XxXX, a joint proposal for a collaborative research and innovation called a Research and Innovation Action (RIA)1, requires the formation of a consortium which includes at least three legal entities from Europe and one legal entity from India. Above the minimum required number of participants (3+1), more European and Indian partners may take part in the proposals (or participants from any country in the world). To ensure adequate participation of all project partners and effective implementation, the project description should clearly describe the role of each partner and their contribution and collaboration in the project. Eligible Indian participants are researchers from recognised public/private funded academic or research institutions, national R&D laboratories; R&D entities having recognition as a Scientific and Industrial Research Organisation (SIRO) by the Department of Scientific and Industrial Research (DSIR) under the Scheme on Recognition of Scientific and Industrial Research Organisations (SIROs) of 1988. The Indian private R&D institutions, Indian NGOs/VOs should be registered in DARPAN Portal of NITI Aayog (xxxx://xxxxxxxxx.xxx.xx/) and registered to Government of India's Public Finance Management System (PFMS)- xxxxx://xxxx.xxx.xx/. • Member States of the European Union, including their overseas departments and outermost regions2 3 4. • Countries Associated to 'Horizon 2020'5; jointly called hereafter 'Europe'. At least three legal entities from Europe shall participate in an action. Each of the three legal European entities shall be established in a different Member State or country associated to 2 xxxxx://xxxxxx.xx/european-union/about-eu/countries_en 3 xxxx://xx.xxxxxx.xx/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-a- countries-rules_en.pdf
Sample 1
AutoNDA by SimpleDocs
Participant Portal. CYC will provide participants with access to CYC’s portal system. This system will allow online claim filing. The participant will also have online access to the following: 1. Real-time history of claim submission and payment process; 2. Account management with transaction history and account balance; 3. Contribution data; and 4. Education tools.
Sample 1

Related to Participant Portal

  • Participant Information My address is: My Social Security Number is:

  • Personnel Participant Conditions The Subrecipient shall include the following clauses in every Subcontract or purchase order, specifically or by reference, so that such provisions will be binding upon each subcontractor or vendor.

  • Participant See Section 7(a) hereof.

  • Participant Responsibilities You must tell the study investigator if you previously took part in this study, have been in any other study in the past year, or are currently involved in any other study. This includes being in the follow-up visit period of another study • You must agree to the scheduled visits, the study plan, lab tests, study procedures, and diet and activity restrictions (details listed later in this document) • You must not have any significant medical or psychiatric condition, as determined by the study investigator, that may put your safety at risk or could have an effect on the study results • Optional Japanese participants must have 4 Japanese biological grandparents who were born in Japan • You must weigh more than 110 lb (99 lb if a Japanese participant) • Your body mass index (BMI) must be between: o Part A, B, and C – 20 -33 kg/m2 o Japanese participants – 16 – 33 kg/m2 • You may be asked to provide documentation of your childbearing status • You must not have a history of phototoxicity or photosensitivity • You must not have a current or past diagnosis of type 1 or type 2 diabetes mellitus • You must not take any medications (including over-the-counter medications, such as medications for cold or allergies, antacids, herbal supplements, minerals, or vitamins) within 7 days before the first dose or at any time during the study o You must not take hormone replacement therapy (HRT) within 28 days before the first dose or at any time during the study ▪ Depo-Provera® must be discontinued at least 6 months before the first dose o Before taking any drugs other than the study drugs, you must call the CRU for approval. It must first be approved by the study investigator o You must tell the study staff about any drugs taken during the study • You must not have taken any medications, dietary or herbal supplements that are inhibitors or inducers of certain enzymes or proteins within 14 days or 5 half-lives (which is drug dependent); before the first dose or at any time during the study o The study investigator or study staff will review a list of these medications and substances with you • You must not take any investigational product (drug or vaccine) within 30 days before the first dose of this study • You must not have a history of sensitivity reactions to midazolam or any of the components of the liquid formulation • You may only participate in one part of this study • You must not have donated blood for at least 60 days before dosing. Plasma (a component of blood) donation may be allowed o You cannot donate any blood or blood products at any time during this study. Donation is not allowed for at least 4 weeks after your last blood draw • You must not have a history of excessive alcohol use or binge drinking and/or other illicit drug use within 6 months before screening o Binge drinking is defined as a pattern of 5 (male) or 4 (female) or more alcoholic drinks in about 2 hours o You should not drink more than 14 alcoholic drinks a week o A drink is defined as 8 oz. (1 cup) of beer, 3 oz. (6 tablespoons) of wine, or 1 oz. (2 tablespoons) of hard liquor • You must not be using/taking any drugs of abuse (such as marijuana, cocaine, opioids, etc.). Urine tests will be done to check for such drugs. o If a test is positive, you will not be allowed in the study o Urine collection may be monitored by a staff member of the same sex o You have the right to refuse to be monitored, but may be disqualified from the study o While in this study, please do not eat anything that contains poppy seeds. They may cause a positive drug test • You must not use tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes or 2 chews of tobacco per day • You must not use tobacco- or nicotine-containing products for 24 hours before the first dose and while confined to the CRU • Please let us know if you or a relative are a staff member of Pfizer. If so, you may not take part in this study if you or your relative are supervised by the study investigator or are directly involved with the study • You will need to stay in the CRU for up to 12 days (Part A) starting with each check-in o Japanese participants will need to stay in the CRU for 12 days starting with check-in o Participants in Group 4 will need to stay in the CRU for 26 days starting with check-in • You will need to stay in the CRU for 19 days (Part B) • You will need to stay in the CRU for 13 days (Part C) • All participants: you may need to stay in the CRU for longer if you experience a longer study drug effect. This is for safety reasons o The study investigator or study staff will decide when it is safe for you to leave the CRU • You must not do any strenuous exercise for at least 48 hours before each blood draw for safety labs. Examples of this include heavy lifting, weight training, or aerobics o Walking at a normal pace is allowed • You may be asked to wear a device (similar to a wristwatch) that can be used to alert study staff in case of an emergency • You will be confined to the procedure room for the first 4 hours during each continuous cardiac monitoring, except to use the bathroom (Part A only) • You cannot lie down for 4 hours after dosing on days when blood samples for study drug levels are collected, unless needed for study procedures • You are advised to avoid direct sunlight or any high intensity UV light exposure from your first admission to the CRU through your last follow-up contact with the CRU o You should apply sunscreen with a sun protection factor (SPF) of greater than or equal to 50 and wear eye-protective sunglasses • You must not eat or drink anything except water for at least 10 hours before each safety laboratory test • You must not eat or drink anything except water for at least 10 hours before collection of the pre- dose blood sample for study drug and other pre-dose blood samples o Except for 1 hour before and 1 hour after dosing (Part A only), you may drink water freely o You can drink water freely if you are in Part B or C • If dosing under fasting conditions (Part A), you must not eat or drink anything (except water) for at least 10 hours before dosing • If dosing under fed conditions (Part A), you must not eat or drink anything except water for at least 10 hours before eating breakfast • If dosing when an OGTT will be done (Parts A and B), you must not eat or drink anything (except water) for at least 10 hours before dosing and/or OGTT • If dosing with a standard breakfast (Part B and C), you must not eat or drink anything (except water) for at least 10 hours before eating breakfast • You must not drink red wine for 7 days before the first dose. Red wine is not allowed through the collection of the last blood sample for study drug • You must not eat or drink anything with alcohol for 24 hours (or as stated above for red wine) before (each) check-in. Alcohol is not allowed through the collection of the last blood sample for study drug in each period o Study staff may check your breath for alcohol. If alcohol is found, you will not be allowed in the study • You must not eat or drink anything with caffeine for 24 hours before dosing. Caffeine is not allowed through the collection of the last blood sample for study drug in each period o Caffeine can be found in different foods and drinks. Some examples include chocolate, coffee, tea, cola, Xx. Xxxxxx®, and Mountain Dew® • You must not eat or drink anything that has grapefruit or grapefruit-related citrus fruits for 7 days before the first dose. These are not allowed through collection of the last blood sample for study drug o Examples of citrus fruits that are not allowed are Seville oranges and pomelos o Fruit juices and smoothies may also contain grapefruit or these citrus fruits • Lunch will be provided about 4–5 hours after dosing • Dinner will be provided about 9-10 hours after dosing • An evening snack may be allowed about 12-13 hours after dosing • If it is necessary to split doses and dose twice a day, the timing of meals or snacks may be changed during • Meals (breakfast, lunch, dinner, and evening snacks) will be provided at appropriate times on all other study days o On non-dosing days while in the CRU, meals and evening snacks will be provided at about the same time as when given on dosing days This study is for research purposes only. There may be no direct benefit to you from taking part. However, information learned from this study may benefit other people in the future. This study is for research purposes only. Your alternative is to not take part in the study.

  • Participant Bound by Plan Participant hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof.

  • Sharing of Participant Information 20 7.4 REPORTING AND DISCLOSURE AND COMMUNICATIONS TO PARTICIPANTS..................................................20 7.5 NON-TERMINATION OF EMPLOYMENT; NO THIRD-PARTY BENEFICIARIES.................................................20 7.6

  • Participant Loans Participant loans, as provided for in paragraph 13.5 of the Basic Plan Document #04, [x] are [ ] are not permitted. If permitted, repayments of principal and interest shall be repaid to [x] the Participant's segregated account or [ ] the general Fund.

  • Participant Contributions If Participant contributions are permitted, complete (a), (b), and (c). Otherwise complete (d).

  • System for Award Management (XXX) Requirement Alongside a signed copy of this Agreement, Grantee will provide Florida Housing with a XXX.xxx proof of registration and Commercial and Government Entity (CAGE) number. Grantee will continue to maintain an active XXX registration with current information at all times during which it has an active award under this Agreement.

  • Participants The Lender and its participants, if any, are not partners or joint venturers, and the Lender shall not have any liability or responsibility for any obligation, act or omission of any of its participants. All rights and powers specifically conferred upon the Lender may be transferred or delegated to any of the Lender's participants, successors or assigns.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!